What Does GLP-1 Actually Cost? A Complete Price Guide

The Short Answer

If you are paying cash, a GLP-1 now costs roughly $99 to $549 per month, and the cheapest reliable route is no longer the one most people expect.

Buying the brand-name drug directly from the manufacturer is now competitive with — and sometimes cheaper than — the telehealth platforms that built their business on compounded copies. Novo Nordisk publishes $349/month for standard Wegovy doses. Eli Lilly publishes $299–$449/month for Zepbound vials. Eligible Medicare patients can pay $50/month through a federal program that opened on July 1, 2026.

Two things changed the math, and both are recent. The FDA ended the shortage exemptions that made mass-produced compounded semaglutide and tirzepatide legal. And the manufacturers responded by opening their own cash-pay pharmacies at prices far below the old list price.

If you last looked at GLP-1 pricing in 2024 or 2025, most of what you learned is out of date.

The compounding era has largely ended

This is the single biggest change, and it undoes the advice most GLP-1 cost guides still give.

Compounded semaglutide and tirzepatide were widely available because both drugs were on the FDA's shortage list, which permits compounding pharmacies to make copies of a drug that patients can't otherwise get. The FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025, then gave compounders wind-down deadlines that all expired by May 22, 2025.

With both drugs off the shortage list, products containing these ingredients are treated as "essentially copies" of an available commercial drug, which restricts compounding to cases where a prescriber documents a meaningful clinical difference for an individual patient. On April 30, 2026 the FDA went further, proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list on the grounds that there is "no clinical need for outsourcing facilities to compound these drugs from bulk substances." Public comment closed June 29, 2026.

What this means for you as a buyer: plenty of telehealth platforms still list compounded semaglutide or tirzepatide on their menus, and personalised compounding for a documented clinical need remains lawful. But the era of cheap, mass-produced compounded GLP-1s as the default budget option is over, and any platform advertising them today is operating in a narrower and more contested space than it was two years ago. Ask directly which pharmacy fills your prescription and on what legal basis before you pay.

What the manufacturers charge directly

Both manufacturers now sell to cash-paying patients through their own pharmacies, at prices they publish openly. These are the numbers to compare everything else against.

Wegovy (semaglutide) — Novo Nordisk

These prices require filling through NovoCare Pharmacy or enrolling in the savings offer. Separately, patients with commercial insurance may pay as little as $25/month through Novo's savings card, capped at $100/month of assistance.

Zepbound (tirzepatide) — Eli Lilly

Announced December 1, 2025, for single-dose vials through the LillyDirect Self-Pay Journey Program:

Read the refill condition. These prices apply when a prescription is refilled within 45 days of the previous delivery. Miss that window and the two highest doses revert to $849/month (12.5 mg) and $1,049/month (15 mg). That is a real trap for anyone whose supply or schedule slips.

Ozempic and Mounjaro

Both are approved for type 2 diabetes rather than weight loss, and both manufacturers now publish cash-pay pricing for them through the same direct channels. Because those figures move and are dose-dependent, check the manufacturer's own price page rather than a third-party summary — the sources are linked at the bottom of this guide.

What telehealth platforms charge

Across the online weight-loss providers listed on VitalityMatch, published monthly prices run $99 to $548 per month, with most including the medication in the monthly fee. Prices below were checked against each company's published pricing on August 25, 2026.

Compare the bottom of that range against the manufacturers and the gap has narrowed sharply. A platform at $99–$199 is still cheaper than $349 direct. A platform at $348–$548 is not — you are paying for the consultation, the coaching and the convenience, and it is worth deciding whether you want those things at that price.

Two questions to ask any platform before paying: which medication am I actually getting, and is the price you quoted the all-in price. See our ranked comparison of online providers for how each one scores on price transparency.

What local clinics charge

Local clinic pricing is the least transparent part of this market, which is why we publish it per clinic rather than as a national average. The structural difference matters more than the headline number: telehealth platforms usually quote one monthly figure with medication included, while local clinics more often charge a consultation fee and then bill medication and lab work separately. Two programs advertising similar monthly numbers can land in very different places once everything is added up.

What a local clinic buys you is in-person physician oversight, metabolic testing and hands-on monitoring. Whether that is worth a premium depends on how complicated your situation is. Browse verified clinics near you to see published pricing where it exists.

What insurance covers

Commercial and employer plans. Coverage for obesity treatment is a separate question from coverage for type 2 diabetes, and plans routinely cover one and not the other. Where a plan does cover weight-loss treatment, it almost always requires prior authorization documenting a BMI of 30 or above, or 27 or above with a weight-related condition. Check your plan's formulary before you assume either way.

Medicare — this changed in 2026. Medicare historically did not cover GLP-1 medications for weight loss. That is no longer the whole picture. CMS launched the Medicare GLP-1 Bridge, a demonstration giving eligible Part D beneficiaries certain GLP-1 drugs at a $50 monthly copay between July 1, 2026 and December 31, 2027. Two conditions worth knowing: the $50 does not count toward your deductible or out-of-pocket maximum, and the program runs outside standard Part D, so your plan does not administer it and low-income subsidies do not apply. Eligibility details are at Medicare.gov.

Medicaid. Coverage still varies by state and most states do not cover GLP-1s for obesity, though the federal picture is shifting. Check your own state's program.

Manufacturer savings programs

If you have commercial insurance, the savings cards are usually the cheapest route of all and are widely underused:

• Novo Nordisk (Wegovy, Ozempic): as little as $25/month, subject to a maximum of $100/month in savings.
• Eli Lilly (Zepbound, Mounjaro): a comparable savings card program through LillyDirect.

Neither applies if you are on Medicare or Medicaid — federal rules prohibit manufacturer copay assistance for government-insured patients. If you are on Medicare, the GLP-1 Bridge above is the program to look at instead.

The bottom line

Start with your insurance, because an approved prior authorization plus a savings card beats every cash price here. If that fails, compare the manufacturer's direct price against the telehealth platforms rather than assuming telehealth wins — since December 2025 it often doesn't.

Use our free GLP-1 cost calculator to narrow this to your own situation, or read how to choose a GLP-1 clinic before you commit to one.

Sources

• FDA — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — shortage resolution dates and compounder wind-down deadlines.
• FDA — FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List — April 30, 2026.
• Novo Nordisk / NovoCare — Wegovy self-pay price guide (PDF) — published Wegovy pen, HD pen and pill prices.
• Novo Nordisk / NovoCare — Wegovy savings offer — savings card terms.
• Eli Lilly — Lilly lowers the price of Zepbound single-dose vials — December 1, 2025, per-dose self-pay prices and the 45-day refill condition.
• CMS — Medicare GLP-1 Bridge — $50 copay, July 1, 2026 to December 31, 2027.
• Telehealth platform pricing: each company's own published pricing page, checked August 25, 2026, and recorded in the VitalityMatch provider directory.

*Prices in this market change often. Every figure above was verified against the source linked beside it on the date shown at the top of this guide. This is not medical advice — talk to a licensed clinician before starting or changing any treatment.*